Interleukin-23 Antagonist [EPC]

68540 reported adverse events

Drugs of this class: GUSELKUMAB TILDRAKIZUMAB-ASMN USTEKINUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-23 Antagonist [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 8578
1 OFF LABEL USE 6332
2 PSORIASIS 5487
3 PRODUCT USE ISSUE 3330
4 PRODUCT DOSE OMISSION ISSUE 2973
5 CROHN^S DISEASE 2806
6 FATIGUE 2568
7 ARTHRALGIA 2386
8 HEADACHE 2354
9 PNEUMONIA 2348
See all common reactions for Interleukin-23 Antagonist [EPC]

Drugs of the Interleukin-23 Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 RED BLOOD CELL SEDIMENTATION RATE 82 0.4940
1 SWOLLEN JOINT COUNT INCREASED 144 0.4472
2 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 711 0.3994
3 RHEUMATOID FACTOR POSITIVE 652 0.3038
4 RHEUMATIC FEVER 156 0.2836
5 CONTRAINDICATION TO VACCINATION 41 0.2455
6 ENTHESOPATHY 198 0.2145
7 PITYRIASIS RUBRA PILARIS 23 0.1840
8 GRANULOMA SKIN 92 0.1685
9 PEMPHIGUS 738 0.1579
See all enriched reactions for Interleukin-23 Antagonist [EPC]